Clinical Trial

Exercise Capacity in Subjects with Heart Failure

Study Description

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Omecamtiv Mecarbil

Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing

Drug - Placebo

Oral placebo twice daily for up to 20 weeks

Additional Information

Official Study Title

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise Tolerance

Clinical Trial ID

NCT03759392

ParticipAid ID

dyPpVb